#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection


The earliest immune responses activated in acute human immunodeficiency virus type 1 infection (AHI) exert a critical influence on subsequent virus spread or containment. During this time frame, components of the innate immune system such as macrophages and DCs, NK cells, β-defensins, complement and other anti-microbial factors, which have all been implicated in modulating HIV infection, may play particularly important roles. A proteomics-based screen was performed on a cohort from whom samples were available at time points prior to the earliest positive HIV detection. The ability of selected factors found to be elevated in the plasma during AHI to inhibit HIV-1 replication was analyzed using in vitro PBMC and DC infection models. Analysis of unique plasma donor panels spanning the eclipse and viral expansion phases revealed very early alterations in plasma proteins in AHI. Induction of acute phase protein serum amyloid A (A-SAA) occurred as early as 5–7 days prior to the first detection of plasma viral RNA, considerably prior to any elevation in systemic cytokine levels. Furthermore, a proteolytic fragment of alpha–1-antitrypsin (AAT), termed virus inhibitory peptide (VIRIP), was observed in plasma coincident with viremia. Both A-SAA and VIRIP have anti-viral activity in vitro and quantitation of their plasma levels indicated that circulating concentrations are likely to be within the range of their inhibitory activity. Our results provide evidence for a first wave of host anti-viral defense occurring in the eclipse phase of AHI prior to systemic activation of other immune responses. Insights gained into the mechanism of action of acute-phase reactants and other innate molecules against HIV and how they are induced could be exploited for the future development of more efficient prophylactic vaccine strategies.


Vyšlo v časopise: Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection. PLoS Pathog 6(5): e32767. doi:10.1371/journal.ppat.1000893
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000893

Souhrn

The earliest immune responses activated in acute human immunodeficiency virus type 1 infection (AHI) exert a critical influence on subsequent virus spread or containment. During this time frame, components of the innate immune system such as macrophages and DCs, NK cells, β-defensins, complement and other anti-microbial factors, which have all been implicated in modulating HIV infection, may play particularly important roles. A proteomics-based screen was performed on a cohort from whom samples were available at time points prior to the earliest positive HIV detection. The ability of selected factors found to be elevated in the plasma during AHI to inhibit HIV-1 replication was analyzed using in vitro PBMC and DC infection models. Analysis of unique plasma donor panels spanning the eclipse and viral expansion phases revealed very early alterations in plasma proteins in AHI. Induction of acute phase protein serum amyloid A (A-SAA) occurred as early as 5–7 days prior to the first detection of plasma viral RNA, considerably prior to any elevation in systemic cytokine levels. Furthermore, a proteolytic fragment of alpha–1-antitrypsin (AAT), termed virus inhibitory peptide (VIRIP), was observed in plasma coincident with viremia. Both A-SAA and VIRIP have anti-viral activity in vitro and quantitation of their plasma levels indicated that circulating concentrations are likely to be within the range of their inhibitory activity. Our results provide evidence for a first wave of host anti-viral defense occurring in the eclipse phase of AHI prior to systemic activation of other immune responses. Insights gained into the mechanism of action of acute-phase reactants and other innate molecules against HIV and how they are induced could be exploited for the future development of more efficient prophylactic vaccine strategies.


Zdroje

1. LiQ

DuanL

EstesJD

MaZM

RourkeT

2005 Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434 1148 1152

2. MattapallilJJ

DouekDC

HillB

NishimuraY

MartinM

2005 Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 1093 1097

3. DeeksSG

WalkerBD

2007 Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27 406 416

4. HaynesBF

ShattockRJ

2008 Critical issues in mucosal immunity for HIV-1 vaccine development. Journal of Allergy and Clinical Immunology 122 3 9

5. McMichaelAJ

BorrowP

TomarasGD

GoonetillekeN

HaynesBF

The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10 11 23

6. FellayJ

ShiannaKV

GeD

ColomboS

LedergerberB

2007 A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science (Washington, DC, United States) 317 944 947

7. JennesW

VerheydenS

DemanetC

Adje-ToureCA

VuylstekeB

2006 Cutting Edge: Resistance to HIV-1 Infection among African Female Sex Workers Is Associated with Inhibitory KIR in the Absence of Their HLA Ligands. Journal of Immunology 177 6588 6592

8. MartinMP

GaoX

LeeJH

NelsonGW

DetelsR

2002 Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31 429 434

9. FengZ

DubyakGR

LedermanMM

WeinbergA

2006 Cutting edge: human beta defensin 3–a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 177 782 786

10. MuenchJ

StaendkerL

AdermannK

SchulzA

SchindlerM

2007 Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (Cambridge, MA, United States) 129 263 275

11. MuenchJ

RueckerE

StaendkerL

AdermannK

GoffinetC

2007 Semen-Derived Amyloid Fibrils Drastically Enhance HIV Infection. Cell 131 1059 1071

12. Gasper-SmithN

CrossmanDM

WhitesidesJF

MensaliN

OttingerJS

2008 Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol 82 7700 7710

13. NorrisPJ

PappalardoBL

CusterB

SpottsG

HechtFM

2006 Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 22 757 762

14. StaceyAR

NorrisPJ

QinL

HaygreenEA

TaylorE

2009 Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of Virology 83 3719 3733

15. FiebigEW

WrightDJ

RawalBD

GarrettPE

SchumacherRT

2003 Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17 1871 1879

16. HusebekkA

PerminH

HusbyG

1986 Serum amyloid protein A (SAA): An indicator of inflammation in AIDS and AIDS-related complex (ARC). Scandinavian Journal of Infectious Diseases 18 389 394

17. UhlarCM

WhiteheadAS

1999 Serum amyloid A, the major vertebrate acute-phase reactant. European Journal of Biochemistry 265 501 523

18. VlasovaMA

MoshkovskiiSA

2006 Molecular interactions of acute phase serum amyloid A: Possible involvement in carcinogenesis. Biochemistry (Moscow) 71 1051 1059

19. MisseD

YsselH

TrabattoniD

ObletC

Lo CaputoS

2007 IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol 178 407 415

20. LiW

SavinovAY

RozanovDV

GolubkovVS

HedayatH

2004 Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha–1-antitrypsin serpin. Cancer Research 64 8657 8665

21. JensenLE

WhiteheadAS

1998 Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 334 489 503

22. DembergT

Robert-GuroffM

2009 Mucosal immunity and protection against HIV/SIV infection: Strategies and challenges for vaccine design. International Reviews of Immunology 28 20 48

23. HeR

ShepardLW

ChenJ

PanZK

YeRD

2006 Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J Immunol 177 4072 4079

24. SongC

HsuK

YamenE

YanW

FockJ

2009 Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 207 374 383

25. BlumenthalR

DimitrovDS

2007 Targeting the sticky fingers of HIV-1. Cell (Cambridge, MA, United States) 129 243 245

26. ShapiroL

PottGB

RalstonAH

2001 Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB Journal 15 115 122

27. NakayamaT

SonodaS

UranoT

YamadaT

OkadaM

1993 Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases. Clinical Chemistry 39 293 297

28. Shainkin-KestenbaumR

ZimlichmanS

WinikoffY

1982 Serum amyloid A (SAA) in viral infection: Rubella, measles and subacute sclerosing panencephalitis (SSPE). Clinical and Experimental Immunology 50 503 506

29. YipTTC

ChanJWM

ChoWCS

YipTT

WangZ

2005 Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clinical Chemistry 51 47 55

30. CaiZ

CaiL

JiangJ

ChangKS

Van Der WesthuyzenDR

2007 Human serum amyloid A protein inhibits hepatitis C virus entry into cells. Journal of Virology 81 6128 6133

31. LavieM

VoissetC

Vu-DacN

ZurawskiV

DuverlieG

2006 Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 44 1626 1634

32. BristowCL

PatelH

ArnoldRR

2001 Self antigen prognostic for human immunodeficiency virus disease progression. Clinical and Diagnostic Laboratory Immunology 8 937 942

33. HayesVM

Gardiner-GardenM

2003 Are Polymorphic Markers within the alpha-1-Antitrypsin Gene Associated with Risk of Human Immunodeficiency Virus Disease? Journal of Infectious Diseases 188 1205 1208

34. AndersonED

ThomasL

HayflickJS

ThomasG

1993 Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha–1-antitrypsin variant. Journal of Biological Chemistry 268 24887 24891

35. McNeelyTB

ShugarsDC

RosendahlM

TuckerC

EisenbergSP

1997 Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90 1141 1149

36. CongoteLF

2006 The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochemical and Biophysical Research Communications 343 617 622

37. CongoteLF

2007 Serpin A1 and CD91 as host instruments against HIV-1 infection: Are extracellular antiviral peptides acting as intracellular messengers? Virus Research 125 119 134

38. HoltzB

CuniasseP

BoulayA

KannanR

MuchaA

1999 Role of the S1' subsite glutamine 215 in activity and specificity of stromelysin-3 by site-directed mutagenesis. Biochemistry 38 12174 12179

39. LiuZ

ZhouX

ShapiroSD

ShipleyJM

TwiningSS

2000 The serpin alpha-1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102 647 655

40. MastroianniCM

LiuzziGM

2007 Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends in Molecular Medicine 13 449 459

41. MellanenL

LähdevirtaJ

TervahartialaT

MeurmanJH

SorsaT

2006 Matrix metalloproteinase-7, -8, -9, -25, and -26 and CD43, -45, and -68 cell-markers in HIV-infected patients' saliva and gingival tissue. Journal of Oral Pathology and Medicine 35 530 539

42. ZhangZ

WinyardPG

ChidwickK

MurphyG

WardellM

1994 Proteolysis of human native and oxidised alpha–1-proteinase inhibitor by matrilysin and stromelysin. Biochimica et Biophysica Acta - General Subjects 1199 224 228

43. ColeAM

2006 Innate host defense of human vaginal and cervical mucosae.

ShaferWM

Current Topics in Microbiology and Immunology 199 230

44. ColeAM

ColeAL

2008 Antimicrobial polypeptides are key anti-hiv-1 effector molecules of cervicovaginal host defense. American Journal of Reproductive Immunology 59 27 34

45. BurgenerA

BoutilierJ

WachihiC

KimaniJ

CarpenterM

2008 Identification of differentially expressed proteins in the cervical mucosa of HIV-1-resistant sex workers. Journal of Proteome Research 7 4446 4454

46. XuD

SuenagaN

EdelmannMJ

FridmanR

MuschelRJ

2008 Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Molecular and Cellular Proteomics 7 2215 2228

47. BatyckaM

InglisNF

CookK

AdamA

Fraser-PittD

2006 Ultra-fast tandem mass spectrometry scanning combined with monolithic column liquid chromatography increases throughput in proteomic analysis. Rapid Communications in Mass Spectrometry 20 2074 2080

48. WesselD

FluggeUI

1984 A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Analytical Biochemistry 138 141 143

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2010 Číslo 5
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#